References
- Yang A , KaghadM, WangY et al. p63, a p53 homolog at 3q27–29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2(3) , 305–316 (1998).
- Gallant-Behm CL , RamseyMR, BensardCL et al. {Delta}Np63α represses anti-proliferative genes via H2A.Z deposition. Genes Dev. 26(20) , 2325–2336 (2012).
- Rocco JW , LeongCO, KuperwasserN, DeyoungMP, EllisenLW. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell9(1) , 45–56 (2006).
- Garcia S , Dalès J-P, Charafe-Jauffret E et al. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum. Pathol.38(6) , 830–841 (2007).
- Deyoung MP , JohannessenCM, Leong C-O, Faquin W, Rocco JW, Ellisen LW. Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma. Cancer Res.66(19) , 9362–9368 (2006).
- Rivetti Di Val Cervo P , LenaAM, NicolosoM et al. p63-microRNA feedback in keratinocyte senescence. Proc. Natl Acad. Sci. USA 109(4) , 1133–1138 (2012).
- Yang A , ZhuZ, KapranovP et al. Relationships between p63 binding, DNA sequence, transcription activity, and biological function in human cells. Mol. Cell 24(4) , 593–602 (2006).
- Ramsey MR , HeL, ForsterN, OryB, EllisenLW. Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma. Cancer Res.71(13) , 4373–4379 (2011).
- Barbieri CE , PerezCA, JohnsonKN, ElyKA, BillheimerD, PietenpolJA. IGFBP-3 is a direct target of transcriptional regulation by DeltaNp63alpha in squamous epithelium. Cancer Res.65 , 2314–2320 (2005).
- Danilov AV , NeupaneD, NagarajaAS et al. DeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes pancreatic cancer cell growth and chemoresistance. PLoS ONE 6 , e26815 (2011).
- Gu L , ZhuN, FindleyHW, ZhouM. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2. Leukemia22(4) , 730–739 (2008).
- Serber Z , LaiHC, YangA et al. A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism. Mol. Cell. Biol. 22(24) , 8601–8611 (2002).
- Ghioni P , BologneseF, DuijfPH, Van Bokhoven H, Mantovani R, Guerrini L. Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains. Mol. Cell. Biol.22(24) , 8659–8668 (2002).
- Barton C , JohnsonKN, MaysD et al. Novel p63 target genes involved in paracrine signaling and keratinocyte differentiation. Cell Death Dis. 1 , e74 (2010).
- Westfall MD , MaysDJ, SniezekJC, PietenpolJA. The Delta Np63 alpha phosphoprotein binds the p21 and 14–13–3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay–Wells syndrome-derived mutations. Mol. Cell. Biol.23(7) , 2264–2276 (2003).
- Boldrup L , CoatesPJ, GuX, NylanderK. DeltaNp63 isoforms regulate CD44 and keratins 4, 6, 14 and 19 in squamous cell carcinoma of head and neck. J. Pathol.213 , 384–391 (2007).
- Wu G , OsadaM, GuoZ et al. DeltaNp63alpha up-regulates the Hsp70 gene in human cancer. Cancer Res. 65(3) , 758–766 (2005).
- Craig AL , HolcakovaJ, FinlanLE et al. DeltaNp63 transcriptionally regulates ATM to control p53 serine-15 phosphorylation. Mol. Cancer 9 , 195 (2010).
- Leboeuf M , TerrellA, TrivediS et al. Hdac1 and Hdac2 act redundantly to control p63 and p53 functions in epidermal progenitor cells. Dev. Cell 19(6) , 807–818 (2010).